A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma.
Dancey G, Violet J, Malaroda A, Green AJ, Sharma SK, Francis R, Othman S, Parker S, Buscombe J, Griffin N, Chan PS, Malhotra A, Woodward N, Ramsay A, Ross P, Lister TA, Amlot P, Begent R, McNamara C.
Dancey G, et al. Among authors: ross p.
Clin Cancer Res. 2009 Dec 15;15(24):7701-7710. doi: 10.1158/1078-0432.CCR-09-1421.
Clin Cancer Res. 2009.
PMID: 20008855